SER · Serina Therapeutics, Inc. · Debt
$1.73
+0.09 (+5.49%)
At close · Oct 29
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that our existing cash and cash equivalents are not expected to be sufficient to fund our operations for the 12 months following the issuance of our unaudited condensed consolidated financial statements for the period ended June 30, 2026, and that substantial doubt about our ability to continue as a going concern continues to exist.”View the 10-Q filed Aug 13, 2026
Market Cap
$44.45M
Shares
25.40M
Volume · Oct 29
18.31K
Avg daily vol (3M)
66.26K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent convertible debt | 2026-06-30 | USD 3,087,000 | 10-Q filed 2026-08-13 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 122,000 | 10-Q filed 2026-08-13 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.